Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus STATROL.
ADVAIR DISKUS 100/50 vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
10 mg orally once daily
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Corticosteroid/LABA Combination
Otic Antibiotic/Corticosteroid